Ronald Williams - Johnson Johnson Independent Director
| JNJ Stock | USD 163.63 0.61 0.37% |
Director
Mr. Ronald A. Williams is an Independent Director of the Company. He served as Chairman and Chief Executive Officer of Aetna Inc. from 2006 to 2010, and as Chairman from 2010 until his retirement in April 2011. He is also an advisor to the private equity firm, Clayton, Dubilier Rice, LLC. In addition, Mr. Williams serves on the boards of MIT Corporationrationration, Peterson Institute for International Economics, the Advisory Board of Peterson Center on Healthcare and is Vice Chairman of the Board of Trustees of The Conference Board. Previously, Mr. Williams served on President Obama Management Advisory Board from 2011 to January 2017, as Chairman of the Council for Affordable Quality Healthcare from 2007 to 2010, and as Vice Chairman of The Business Council from 2008 to 2010. since 2011.
| Age | 71 |
| Tenure | 14 years |
| Address | One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Ronald Williams Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ronald Williams against Johnson Johnson stock is an integral part of due diligence when investing in Johnson Johnson. Ronald Williams insider activity provides valuable insight into whether Johnson Johnson is net buyers or sellers over its current business cycle. Note, Johnson Johnson insiders must abide by specific rules, including filing SEC forms every time they buy or sell Johnson Johnson'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ronald Williams over a year ago Acquisition by Ronald Williams of 467 shares of Boeing subject to Rule 16b-3 | ||
Ronald Williams over a year ago Acquisition by Ronald Williams of 1428 shares of Johnson Johnson subject to Rule 16b-3 | ||
Ronald Williams over a year ago Acquisition by Ronald Williams of 258 shares of Boeing subject to Rule 16b-3 | ||
Ronald Williams over a year ago Acquisition by Ronald Williams of 498 shares of Boeing subject to Rule 16b-3 |
Johnson Johnson Management Efficiency
The company has Return on Asset of 0.0813 % which means that on every $100 spent on assets, it made $0.0813 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2006 %, implying that it generated $0.2006 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.25 this year, although the value of Return On Assets will most likely fall to 0.13. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 202.3 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kathy Warden | Merck Company | 49 | |
| Peter Wendell | Merck Company | 70 | |
| Carolyn Bertozzi | Eli Lilly and | 53 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
| Gerald Storch | Bristol Myers Squibb | 64 | |
| Rebecca Roberts | AbbVie Inc | 68 | |
| Leslie Brun | Merck Company | 68 | |
| James Smith | Pfizer Inc | 61 | |
| Helen Hobbs | Pfizer Inc | 68 | |
| James Kilts | Pfizer Inc | 71 | |
| William Kaelin | Eli Lilly and | 63 | |
| Inge Thulin | Merck Company | 67 | |
| Christine Seidman | Merck Company | 68 | |
| Katherine Baicker | Eli Lilly and | 49 | |
| Suzanne Johnson | Pfizer Inc | 63 | |
| Edward Rapp | AbbVie Inc | 63 | |
| Jackson Tai | Eli Lilly and | 71 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Robert Alpern | AbbVie Inc | 70 | |
| Joseph Echevarria | Pfizer Inc | 64 | |
Management Performance
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0813 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Duane Arsdale, Treasurer | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Jasmina Brooks, President Webster | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Nadja West, Independent Director | ||
| Mark Larkins, Worldwide Secretary | ||
| Joanne MD, Chief Officer | ||
| Vanessa Broadhurst, Executive Vice President Global Corporate Affairs | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Tom Cavanaugh, Company Medicine | ||
| D Davis, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Ian Davis, Independent Director | ||
| Mark Weinberger, Independent Director | ||
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Elizabeth JD, Executive Officer | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Executive CFO | ||
| Michael Bodner, Global Recovery | ||
| Mary Beckerle, Independent Director | ||
| Darius Adamczyk, Independent Director | ||
| Susan MD, Vice Officer | ||
| Hani Abouhalka, Company Digital | ||
| Ahmet Tezel, Group RD | ||
| Frederic MD, Chief Group | ||
| Robert Decker, Controller Officer | ||
| Mathai Mammen, Executive Vice President Pharmaceuticals, R&D | ||
| Timothy Schmid, Executive MedTech | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | ||
| James Swanson, Executive Vice President, Chief Information Officer | ||
| Hubert Joly, Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health | ||
| Jessica Moore, Vice Relations | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Celine Martin, Group CSS | ||
| Kristen Mulholland, Executive Officer | ||
| Elizabeth Forminard, Executive Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Guy MD, Group EMEA | ||
| David Lee, Immunology Head |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0813 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 404.97 B | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 73.56 % | ||||
| Number Of Shares Shorted | 23.1 M | ||||
| Price To Earning | 24.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Dividend Share 4.91 | Earnings Share 5.79 | Revenue Per Share | Quarterly Revenue Growth 0.053 |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.